

Board of Directors

Item 5.1

Subject: High Risk Report
Date of meeting: 27th September 2023
Presented by: Karan Wheatcroft, Director of Risk and Improvement
Purpose of report: To Note

BAF Reference	Impact on BAF
All	The report includes high level risks which continue to be considered in respect of any implications for the BAF.

Level of assurance (please tick one)					
<input checked="" type="checkbox"/>	Acceptable assurance	<input type="checkbox"/>	Partial assurance	<input type="checkbox"/>	Low assurance
	Controls are suitably designed, with evidence of them being consistently applied and effective in practice		Controls are still maturing – evidence shows that further action is required to improve their effectiveness		Evidence indicates poor effectiveness of controls

1. Executive Summary

The Corporate Risk Register contains significant risks identified as having potential impact on the trust corporate objectives, including risks identified and escalated by Divisions. Risks are reviewed monthly at each Divisional Governance meeting and quarterly by the Risk Management Committee.

This report provides an update of risks with residual scores of 15 or higher along with the action plans in place to control and/or mitigate them.

Whilst there are no risks with a score of 15 or higher on the Trust's Risk Register, the Executive Team are currently reviewing the risk regarding statutory waiting times and operational delivery. This risk was reduced from a residual risk score of 16 to 12 in Quarter 1 of 2023/24. The continued uncertainty and impact of industrial action, along with theatre staffing constraints and operational challenges (including cancellations) are contributing to a heightened risk in this area. A thorough review of risk mitigations is being undertaken and this will be reflected in the high risk report and Board Assurance Framework (BAF 2) for Q2.

2. Recommendation

The Board are asked to note the report and be assured the Trust has systems and processes in place for the identification, management and escalation of risks.